| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454851 | Lung Cancer | 2015 | 7 Pages |
Abstract
While ALK status can be determined robustly for the majority of NSCLC by FISH our analysis showed that â¼6% of the cases belong to a borderline group for which ALK-FISH evaluation has only limited reliability due to statistical sampling effects. These cases should be considered equivocal and therapy decisions should include additional tests and clinical considerations.
Keywords
LCCFDAfluorescence in-situ hybridization (FISH)TKIADSCSRSNOSEMACNGHER2SCCADCAdenocarcinomaALKEuropean Medicines agencyCopy number gainImmunohistochemistryIHCimmunohistochemistry (IHC)Statistical analysisNot otherwise specifiedFood and Drug AdministrationNon-small cell lung cancer (NSCLC)NSCLCNon-small cell lung cancerAnaplastic lymphoma kinaseAnaplastic lymphoma kinase (ALK)Fishfalse positiveBorderlinefalse negativeTyrosine kinase inhibitorFluorescence in-situ hybridizationAdenosquamous carcinomaLarge cell carcinomaSquamous cell carcinomahuman epidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maximilian von Laffert, Albrecht Stenzinger, Michael Hummel, Wilko Weichert, Dido Lenze, Arne Warth, Roland Penzel, Hermann Herbst, Udo Kellner, Philipp Jurmeister, Peter Schirmacher, Manfred Dietel, Frederick Klauschen,